Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06217783

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Oncologic Complications and Emergencies Disease Attributes Emergencies Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

MD Anderson Cancer Center

Houston, Texas, 77030, United States

Location status: Recruiting

About this study

Primary Objectives:

  • The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.

Secondary Objectives:

  • Time from catheter placement to removal (i.e. survival or dwell time).
  • Per catheter length rate of failure analysis
  • Rate of repeat catheterization
  • Rate of infection
  • Rate of thrombosis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18 years old.
  • Provision of signed and dated informed consent form.
  • Predetermined to have difficult IV access necessitating USIV placement
  • Expected admission to hospital with anticipated stay > 48 hours (per discussion with treating physician).

Exclusion criteria

  • Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
  • Inability to give informed consent.
  • Pregnant women.
  • Non-English speaking participants.

Treatment and study plan

Introcan Safety IV Catheter

Device

Given by IV

Primary outcomes

  1. Safety and adverse events (AEs)

    Time frame: Through study completion; an average of 1 year.

    Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)

Interested in participating?

Recruiting

Interested in participating?

Request Info

Sponsors and collaborators

Lead sponsor

M.D. Anderson Cancer Center

Other

Registry information

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Jan 22, 2024
Registry last updated
Jun 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.